{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:05:47Z","timestamp":1740135947161,"version":"3.37.3"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gia","award":["442225\/2014-8"],"award-info":[{"award-number":["442225\/2014-8"]}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"crossref","award":["BEX 7715-15-3"],"award-info":[{"award-number":["BEX 7715-15-3"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Ci\u00eancia e Tecnologia de Pernambuco","award":["APQ-0599-2.02\/14"],"award-info":[{"award-number":["APQ-0599-2.02\/14"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Neuropsychiatric adverse effects (NPAE) related to efavirenz, mainly dizziness, is detrimental to human immunodeficiency virus (HIV) treatment. Our study aims at evaluating if zidovudine use potentiates the risk of dizziness related to efavirenz when used together and whether there are significant differences in over time distribution of this NPAE and others relatively frequents regarding efavirenz regimen without zidovudine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Human immunodeficiency virus-infected patients under efavirenz-containing different therapy were enrolled. A retrospective analysis of official medical records was accomplished to collect clinical data regarding NPAE occurrence and severity. Univariate statistic and statistical model based on survival analyses were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>One hundred sixty-two patients were included, of these seventy-seven (47.5%) had NPAE reported, such as dizziness (more frequent), depression and insomnia. Univariate statistical analysis demonstrated that the combined use of efavirenz with zidovudine increased the NPAE risk (OR: 2.5; P-value: 0.008), mainly dizziness risk (OR: 3.5; P-value: 0.009) and survival analysis showed that such combination is associated with dizziness occurrence faster (HR: 2.9; P-value: 0.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results may contribute to clarify the dizziness occurrence dynamics in therapy with efavirenz and zidovudine by identifying susceptibilities and assisting in the choice of combined antiretroviral therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.13237","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:59:10Z","timestamp":1581415150000},"page":"719-727","source":"Crossref","is-referenced-by-count":1,"title":["Increased risk of dizziness in human immunodeficiency virus-infected patients taking zidovudine and efavirenz combination: a Brazilian cohort study"],"prefix":"10.1093","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2775-8685","authenticated-orcid":false,"given":"Josu\u00e9 Jeyzon de Lima Soares","family":"Valeriano","sequence":"first","affiliation":[{"name":"Department of Genetics, Federal University of Pernambuco , Recife, PE,","place":["Brazil"]},{"name":"Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco , Recife, PE,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wlisses Henrique Veloso","family":"Carvalho-Silva","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco , Recife, PE,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio Victor Campos","family":"Coelho","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco , Recife, PE,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald Rodrigues","family":"Moura","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco , Recife, PE,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Cl\u00e1udio","family":"Arraes","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco , Recife, PE,","place":["Brazil"]},{"name":"Institute of Integral Medicine Professor Fernando Figueira (IMIP) , Recife, PE,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Andr\u00e9 Cavalcanti","family":"Brand\u00e3o","sequence":"additional","affiliation":[{"name":"Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco , Recife, PE,","place":["Brazil"]},{"name":"Department of Pathology, Federal University of Pernambuco , Recife, PE,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Crovella","sequence":"additional","affiliation":[{"name":"Department of Genetics, Federal University of Pernambuco , Recife, PE,","place":["Brazil"]},{"name":"IRCCS Burlo Garofolo, University of Trieste , Trieste,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Lima","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Department of Genetics, Federal University of Pernambuco , Recife, PE,","place":["Brazil"]},{"name":"Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco , Recife, PE,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"2024103012343332500_jphp13237-cit-0001","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/QAI.0000000000000606","article-title":"Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials","volume":"69","author":"Ford","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"volume-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Manejo da Infec\u00e7\u00e3o pelo HIV em Adultos","author":"Minist\u00e9rio da Sa\u00fade","key":"2024103012343332500_jphp13237-cit-0002"},{"volume-title":"Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidance","year":"2018","author":"WHO","key":"2024103012343332500_jphp13237-cit-0003"},{"key":"2024103012343332500_jphp13237-cit-0004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/13550281003767710","article-title":"Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?","volume":"16","author":"Mu\u00f1oz-Moreno","year":"2010","journal-title":"J Neurovirol"},{"key":"2024103012343332500_jphp13237-cit-0005","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/pgs.13.111","article-title":"Impact of pharmacogenetics on CNS side effects related to efavirenz","volume":"14","author":"S\u00e1nchez Mart\u00edn","year":"2013","journal-title":"Pharmacogenomics"},{"key":"2024103012343332500_jphp13237-cit-0006","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1517\/14740338.2013.823396","article-title":"Neuronal toxicity of efavirenz: a systematic review","volume":"12","author":"Decloedt","year":"2013","journal-title":"Exp Opin Drug Saf"},{"key":"2024103012343332500_jphp13237-cit-0007","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40264-016-0440-y","article-title":"Neuropsychiatric effects of HIV antiviral medications","volume":"39","author":"Treisman","year":"2016","journal-title":"Drug Saf"},{"key":"2024103012343332500_jphp13237-cit-0008","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/jac\/dkv183","article-title":"Efavirenz and the CNS: what we already know and questions that need to be answered","volume":"70","author":"Apostolova","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024103012343332500_jphp13237-cit-0009","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/phar.1728","article-title":"Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy","volume":"36","author":"Scott Sutton","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2024103012343332500_jphp13237-cit-0010","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/pr.111.005553","article-title":"The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition","volume":"64","author":"Michaud","year":"2012","journal-title":"Pharmacol Rev"},{"key":"2024103012343332500_jphp13237-cit-0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0179769","article-title":"A decade of HAART in Latin America: long term outcomes among the first wave of HIV patients to receive combination therapy","volume":"12","author":"Wolff","year":"2017","journal-title":"PLoS ONE"},{"key":"2024103012343332500_jphp13237-cit-0012","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1310\/hct1006-343","article-title":"Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)","volume":"10","author":"Clifford","year":"2009","journal-title":"HIV Clin Trials."},{"key":"2024103012343332500_jphp13237-cit-0013","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40263-013-0132-4","article-title":"Neurological and psychiatric adverse effects of antiretroviral drugs","volume":"28","author":"Abers","year":"2014","journal-title":"CNS Drugs"},{"key":"2024103012343332500_jphp13237-cit-0014","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1212\/WNL.0b013e31821670fb","article-title":"Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients","volume":"7","author":"Ciccarelli","year":"2011","journal-title":"Neurology"},{"key":"2024103012343332500_jphp13237-cit-0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s13365-015-0382-7","article-title":"Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients","volume":"22","author":"Ma","year":"2016","journal-title":"J Neurovirol"},{"key":"2024103012343332500_jphp13237-cit-0016","first-page":"499","article-title":"Evaluating medication adherence: which measure is right for your program?","volume":"6","author":"Fairman","year":"2000","journal-title":"J Manag Care Pharm"},{"key":"2024103012343332500_jphp13237-cit-0017","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1176\/jnp.2010.22.4.361","article-title":"Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm","volume":"22","author":"S\u00fctterlin","year":"2010","journal-title":"J Neuropsy Clin Neurosci"},{"key":"2024103012343332500_jphp13237-cit-0018","first-page":"103","article-title":"Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A Neurobehavioral review","volume":"11","author":"Mu\u00f1oz-Moreno","year":"2010","journal-title":"Aids Rev"},{"key":"2024103012343332500_jphp13237-cit-0019","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","article-title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis","volume":"3","author":"Kanters","year":"2016","journal-title":"The Lancet HIV"},{"key":"2024103012343332500_jphp13237-cit-0020","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1093\/jac\/dky298","article-title":"High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily","volume":"73","author":"Seden","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024103012343332500_jphp13237-cit-0021","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1080\/17512433.2016.1221760","article-title":"Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen","volume":"9","author":"Mouton","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024103012343332500_jphp13237-cit-0022","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012343332500_jphp13237-cit-0023","doi-asserted-by":"crossref","first-page":"507","DOI":"10.5414\/CPP40507","article-title":"Population pharmacokinetic meta-analysis with efavirenz","volume":"40","author":"Barrett","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2024103012343332500_jphp13237-cit-0024","doi-asserted-by":"crossref","first-page":"18567","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"2024103012343332500_jphp13237-cit-0025","first-page":"483","article-title":"Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy","volume":"8","author":"Curkendall","year":"2007","journal-title":"Br HIV Assoc"},{"key":"2024103012343332500_jphp13237-cit-0026","first-page":"115","article-title":"Incidence of anaemia among HIV-infected patients treated with zidovudine-containing antiretroviral therapy in Northeastern Nigeria","volume":"16","author":"Ikunaiye","year":"2018","journal-title":"Ann Ibd Pg Med"},{"key":"2024103012343332500_jphp13237-cit-0027","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1124\/dmd.109.027706","article-title":"Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine","volume":"37","author":"B\u00e9langer","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"2024103012343332500_jphp13237-cit-0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.2014.930128","article-title":"Pharmacogenetics of antiretroviral therapy","volume":"10","author":"Barreiro","year":"2014","journal-title":"Exp Opin Drug Metab Toxicol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jphp.13237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jphp.13237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/5\/719\/60225661\/jphp13237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/5\/719\/60225661\/jphp13237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:53:27Z","timestamp":1730310807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/72\/5\/719\/6122030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.13237","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5,1]]}}}